Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Gastrin-SiO2 refers to a pharmaceutical formulation in which the peptide hormone gastrin is encapsulated or adsorbed onto silica (silicon dioxide) microspheres. This combination leverages the biological activity of gastrin—a hormone that stimulates gastric acid secretion and promotes gastrointestinal motility—while using silica microspheres as a delivery vehicle to potentially enhance stability, control release, or target delivery within the body. Gastrin acts primarily by binding to cholecystokinin B receptors on parietal and enterochromaffin-like cells in the stomach, leading to increased gastric acid secretion and other digestive effects[4][1]. The use of SiO2 (silica) as a carrier may be intended for improved pharmacokinetics or targeted therapy applications.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on gastrin-SiO2.